Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments
Authors:
Open Access
- 30 October 2013
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 2 (10) , 1-8
Abstract
Late‐phase clinical trials within diabetes generally have a duration of 12–24 weeks, where 12 weeks may be too short to reach steady‐state glycated hemoglobin (HbA1c). The main determinant for HbA1c is blood glucose, which reaches steady state much sooner. In spite of this, few publications have used individual data to assess the time course of both glucose and HbA1c, for predicting HbA1c. In this paper, we present an approach for predicting HbA1c at end‐of‐trial (24–28 weeks) using glucose and HbA1c measurements up to 12 weeks. The approach was evaluated using data from 4 trials covering 12 treatment arms (oral antidiabetic drug, glucagon‐like peptide‐1, and insulin treatment) with measurements at 24–28 weeks to evaluate predictions vs. observations. HbA1c percentage was predicted for each arm at end‐of‐trial with a mean prediction error of 0.14% [0.01;0.24]. Furthermore, end points in terms of HbA1c reductions relative to comparator were accurately predicted. The proposed model provides a good basis to optimize late‐stage clinical development within diabetes.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e82; doi:10.1038/psp.2013.58; advance online publication 30 October 2013Keywords
This publication has 21 references indexed in Scilit:
- The relationship between self‐monitored blood glucose values and glycated haemoglobin in insulin‐treated patients with Type 2 diabetesDiabetic Medicine, 2010
- Simple pharmacometric tools for oral anti‐diabetic drug development: competitive landscape for oral non‐insulin therapies in type 2 diabetesBiopharmaceutics & Drug Disposition, 2010
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)Diabetes Care, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Translating the A1C Assay Into Estimated Average Glucose ValuesDiabetes Care, 2008
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- Pharmacokinetic/Pharmacodynamic Modelling in??Diabetes MellitusClinical Pharmacokinetics, 2008
- Variability in the Relationship between Mean Plasma Glucose and HbA1c: Implications for the Assessment of Glycemic ControlClinical Chemistry, 2007
- Initiating Insulin Therapy in Type 2 DiabetesDiabetes Care, 2005
- A theoretical model to predict the behavior of glycosylated hemoglobin levelsJournal of Theoretical Biology, 1979